title: Interleukin-1β induces a reversible cardiomyopathy in the mouse.
abstract: BACKGROUND
  Inflammatory mediators play a key role in the development and progression of heart failure. Interleukin-1β (IL-1β) is a prototypical inflammatory cytokine that suppresses myocyte contractility following acute administration.
  
  
  METHODS
  Healthy mice were randomly assigned to daily intraperitoneal injections of recombinant murine IL-1β (3 μg/kg in 0.2 ml) or matching volumes of NaCl 0.9 % solution (vehicle) for 15 days. Echocardiography was performed at baseline and 4 h (acute), followed by repeat measurements immediately prior to IL-1β or saline injections on days 5, 10, and 15 (chronic). Final echocardiography was performed on day 20 (5 days after last treatment). A subgroup of animals underwent isoproterenol challenge to evaluate contractile reserve at baseline, 4 h (acute), 15 days (chronic) and 20 days (recovery).
  
  
  RESULTS
  IL-1β reduced left ventricular fractional shortening (LVFS) at 4 h versus vehicle (-24 vs. 0 %, respectively, P < 0.05). This reduction was maintained throughout chronic dosing at day 15. IL-1β-treated mice also showed impaired contractile reserve with a right shift of the dose-response curve to isoproterenol (P < 0.05) at 4 h and 15 days. By day 20, 5 days after stopping IL-1β, LVFS and contractile reserve had returned to baseline.
  
  
  CONCLUSIONS
  IL-1β induces a reversible contractile dysfunction associated with impaired response to β-receptor stimulation.
authors: Pharmacotherapy and Outcome Sciences, School of Pharmacy, Richmond, USA. bvantassell@vcu.edu
authors: Benjamin W
authors: BW
authors: Van Tassell
authors: Ignacio M
authors: IM
authors: Seropian
authors: Stefano
authors: S
authors: Toldo
authors: Eleonora
authors: E
authors: Mezzaroma
authors: Antonio
authors: A
authors: Abbate
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000503:physiopathology; D053583:Interleukin-1beta / Q000008:administration & dosage / Q000009:adverse effects*; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D051379:Mice; D009200:Myocardial Contraction / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000318:Adrenergic beta-Agonists; D053583:Interleukin-1beta; D007545:Isoproterenol
references: Circulation. 2010 Nov 9;122(19):1975-96
references: 20937981
references: BioDrugs. 2012 Aug 1;26(4):217-33
references: 22571369
references: Circulation. 2012 Jan 3;125(1):e2-e220
references: 22179539
references: Expert Rev Cardiovasc Ther. 2012 Feb;10(2):215-21
references: 22292877
references: Circulation. 2001 Apr 24;103(16):2055-9
references: 11319194
references: Am J Physiol. 1988 Oct;255(4 Pt 2):H699-703
references: 3177662
references: J Heart Lung Transplant. 2010 Mar;29(3):382-4
references: 19875310
references: J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):61A-71A
references: 8397233
references: J Cell Physiol. 2003 Apr;195(1):1-11
references: 12599203
references: Proc Natl Acad Sci U S A. 1989 Sep;86(17):6753-7
references: 2549546
references: Chest. 2010 Jul;138(1):198-207
references: 20605820
references: Am J Physiol. 1999 Jan;276(1):R265-76
references: 9887205
references: Blood. 2011 Apr 7;117(14):3720-32
references: 21304099
references: PLoS One. 2012;7(3):e33438
references: 22438931
references: Am J Physiol. 1999 Jan;276(1):H141-8
references: 9887027
references: Ann Intern Med. 1984 Apr;100(4):483-90
references: 6703540
references: J Am Soc Echocardiogr. 2002 Mar;15(3):275-90
references: 11875394
references: N Engl J Med. 2009 Apr 9;360(15):1526-38
references: 19357408